Hruza C, Dobianer K, Beck A, Czerwenka K, Hanak H, Klein M, Leodolter S, Medl M, Müllauer-Ertl S, Preiser J
Ludwig Boltzmann Institute of Experimental Endocrinology, Department of Cellular Endocrinology, University of Vienna, Austria.
Eur J Cancer. 1993;29A(11):1593-7. doi: 10.1016/0959-8049(93)90301-u.
Competitive polymerase chain reaction (PCR) systems were developed for rapid and quantitative estimation of HER-2 (c-erbB-2) and INT-2 oncogene amplification in paraffin-embedded ovarian cancer tissue samples. The beta-globin gene was used as reference and DNA from paraffin-embedded placenta tissue as single copy control. Reliability of the PCR method could be demonstrated by comparing dot blot data with PCR data of identical tumour samples. The PCR method was used to determine HER-2 and INT-2 copy numbers in 196 ovarian cancer samples. HER-2 and INT-2 were found to be amplified in 40 and 19%, respectively. In 8% HER-2 copy numbers were greater than five, but no high INT-2 copies were noted. Kaplan-Meier estimates did not reveal significant association with overall survival. Indirect correlation between HER-2 and INT-2 amplification was observed. The present PCR system is a valuable method for prospective and retrospective studies.
竞争性聚合酶链反应（PCR）系统被开发用于快速定量评估石蜡包埋的卵巢癌组织样本中HER-2（c-erbB-2）和INT-2癌基因的扩增情况。β-珠蛋白基因用作参照，石蜡包埋的胎盘组织DNA作为单拷贝对照。通过比较相同肿瘤样本的斑点印迹数据和PCR数据，可证明PCR方法的可靠性。PCR方法用于测定196份卵巢癌样本中的HER-2和INT-2拷贝数。发现HER-2和INT-2的扩增率分别为40%和19%。8%的样本中HER-2拷贝数大于5，但未发现高INT-2拷贝数。Kaplan-Meier估计未显示与总生存期有显著关联。观察到HER-2和INT-2扩增之间存在间接相关性。目前的PCR系统是前瞻性和回顾性研究的一种有价值的方法。
